The Exciting Future of Medicine with Pablo Lapuerta

Published April 15, 2020 in Business Today Online Journal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Published January 14, 2021 in The New England Journal of Medicine

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Published January 14, 2021 in The New England Journal of Medicine

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies

Published November 1, 2020 in Diabetes Care

Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study

Published July 30, 2020 in Cancer Management and Research

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

Published March 7, 2020 in Journal of Gastrointestinal Cancer

Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues

Published July 17, 2019 in Clinical Therapeutics

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: A systematic review and meta-analysis

Published February 8, 2019 in Future Oncology

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

Published December 14, 2017 in the The New England Journal of Medicine

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Published January 1, 2017 in Journal of Clinical Oncology